# 2025-21179: Importer of Controlled Substances Application: Caligor Coghlan Pharma Services

2025-21179, Importer of Controlled Substances Application: Caligor Coghlan Pharma Services, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-11-26, effective Registered bulk manufacturers of the affected basic class(es), and applicants, may submit electronic comments on or objections to the issuance of the proposed registration on or before December 26, 2025. Such persons may also file a written request for a hearing on the application on or before December 26, 2025. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-21179
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-21179
- Title: Importer of Controlled Substances Application: Caligor Coghlan Pharma Services
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 54370
- Published: 2025-11-26
- Effective: Registered bulk manufacturers of the affected basic class(es), and applicants, may submit electronic comments on or objections to the issuance of the proposed registration on or before December 26, 2025. Such persons may also file a written request for a hearing on the application on or before December 26, 2025.
- Comments close: 2025-12-26
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## Summary

Caligor Coghlan Pharma Services wants to become an official importer of certain controlled substances, including some powerful drugs like LSD. People and companies involved with these drugs can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances are brought into the U.S., but no costs or fees are mentioned yet.

## Abstract

Caligor Coghlan Pharma Services has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

## Effects PRIA read

- Importer Application for Schedule I Drugs: benefit, medium. Caligor Coghlan Pharma Services applied on July 24, 2025 to be registered to import these Schedule I finished dosage units for clinical trials: lysergic acid diethylamide (LSD, code 7315), 5‑Methoxy‑N‑N‑dimethyltryptamine (code 7431), dimethyltryptamine (DMT, code 7435), and psilocyn (code 7438). T…
- No Commercial Sale Import Authorization: cost, medium. The notice explicitly says authorization will not extend to import of FDA‑approved or non‑approved finished dosage forms for commercial sale. If you planned to import these drugs for commercial sale, this registration would not permit that activity.
- Comment and Hearing Deadline: Dec 26, 2025: benefit, low. Registered bulk manufacturers of the affected drug classes, applicants, and other interested parties may submit electronic comments or objections, or file a written request for a hearing, on or before December 26, 2025. Comments must be submitted through Regulations.gov; hearing requests must be fi…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-21179 on federalregister.gov](https://www.federalregister.gov/documents/2025/11/26/2025-21179/importer-of-controlled-substances-application-caligor-coghlan-pharma-services)
- [2025-21179 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-11-26/pdf/2025-21179.pdf)

## Related
- [Previous: 2025-21178, Importer of Controlled Substances Application: Siegfried Grafton, Inc.](https://policyrisk.com/federal-register/2025-21178)
- [Next: 2025-21180, Importer of Controlled Substances Application: NSI Lab Solutions, LLC.](https://policyrisk.com/federal-register/2025-21180)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-21179 (as of 2026-06-08).
